Welcome to the Health and Medical Special 2026 Edition of Business Enquirer Magazine
Healthcare has always been defined by innovation. Yet in 2026, innovation alone is no longer enough. Scientific breakthroughs remain essential, but increasingly the organisations shaping the future of pharmaceuticals are those capable of transforming discovery into delivery. The challenge is no longer simply developing the next generation
of therapies. It is building the infrastructure, systems and expertise required to bring them to patients faster, more efficiently and at greater scale than ever before.
This special edition explores the businesses, technologies and leaders helping to redefine what modern pharmaceutical innovation looks
like.
We focus on Curium and Chief Executive Officer Renaud Dehareng, whose vision for nuclear medicine reflects one of the most significant shifts currently taking place within oncology. As radiopharmaceuticals move from specialist treatment to mainstream cancer care, Curium has positioned itself at the centre of a rapidly evolving field. The company’s story is one of conviction, reinvestment and long-term thinking, demonstrating how scientific ambition must be supported by operational excellence if it is to create meaningful patient impact.
That balance between innovation and execution runs throughout this edition. At PlasmaGen, we examine how leadership, infrastructure and strategic investment are helping to strengthen access to plasma-derived therapies across India and beyond. What emerges is a powerful example of how healthcare resilience is built not only through scientific capability, but through the creation of sustainable ecosystems capable of delivering treatments reliably and affordably.
The growing role of digitalisation is another defining theme. Features on ZETA and Helbling explore how digital twins, connected data environments and intelligent manufacturing systems are transforming pharmaceutical development and production. In an industry where speed, compliance and quality must coexist, these technologies are becoming far more than operational tools. They are becoming strategic assets that reshape how organisations design, build and scale innovation.
Artificial intelligence also continues to move from promise to practical application. Our conversation with Merck examines how advanced retrosynthesis platforms are helping researchers accelerate drug discovery, while our news coverage explores the wider adoption of AI across laboratories, manufacturing facilities and regulatory environments. The common thread is clear. AI is no longer an emerging technology within pharmaceuticals. It is becoming part of the industry’s operational foundation.
Alongside these transformations, we also explore the people shaping the sector. From leadership perspectives at PharmaBlock to the collaborative ecosystems supporting global pharmaceutical growth, this edition highlights the importance of culture, talent and shared purpose in driving long-term success.
Across every feature, a consistent pattern emerges. The future of pharmaceuticals will not be determined by scientific breakthroughs alone. It will be defined by the ability to connect research with manufacturing, technology with regulation, and innovation with patient outcomes. The organisations leading this transition understand that progress depends not simply on what can be discovered, but on what can be delivered.
If you have a business story you wish to share, please contact our Head of Production via production@busenq.com